| Views | |
|---|---|
| 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years | 104 |
| January 2025 | February 2025 | March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | |
|---|---|---|---|---|---|---|---|
| 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years | 10 | 10 | 6 | 2 | 13 | 10 | 1 |
| Views | |
|---|---|
| 2022_Rieger_etal.pdf | 25 |
